Consider Cardiovascular Benefits When Recommending a GLP-1 Agonist

August 2019

Trulicity (dulaglutide) will be the third GLP-1 agonist to show CV benefits in some patients with type 2 diabetes.

It joins Ozempic (semaglutide) and Victoza (liraglutide). All three lower CV risk in type 2 patients with CV disease or at high CV risk.

Each of these meds also seems to slow progression to albuminuria...but isn't shown to delay dialysis.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote